Details for Patent: 10,016,372
✉ Email this page to a colleague
Which drugs does patent 10,016,372 protect, and when does it expire?
Patent 10,016,372 protects ADLARITY and is included in one NDA.
This patent has seventy-two patent family members in ten countries.
Summary for Patent: 10,016,372
| Title: | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| Abstract: | A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25. |
| Inventor(s): | Singh; Parminder (Union City, CA), Lee; Eun Soo (Redwood City, CA), Jain; Amit K. (Milpitas, CA) |
| Assignee: | Corium International, Inc. (Menlo Park, CA) |
| Application Number: | 15/660,933 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 10,016,372
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | ||||
| Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,016,372
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017301928 | ⤷ Try a Trial | |||
| Australia | 2017301929 | ⤷ Try a Trial | |||
| Australia | 2017302305 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
